Infant Bacterial Therapeutics AB
Graf
Viktig: Aksjeinvesteringer kan over tid gi positiv avkastning, men innebærer risiko. Du kan tape deler av eller hele investeringen. Historisk avkastning for denne aksjen er ikke en pålitelig indikator på fremtidig avkastning. Data fra eksterne leverandører gjengis uendret av Saxo. Se fullstendig ansvarsfraskrivelse for data.
Om Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118 and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.
/ 